The iconic rise of Viagra has long been a benchmark of pharmaceutical success, however its future within the broader sector now raises questions about potential gains. Copycat versions are eroding market share, causing worries that investing in companies heavily reliant to Viagra's once-dominant position could be a speculative strategy, especially